PRODUCT DATA SHEET

AG-CN2-0444

Salinosporamide A
[SalA; Marizomib; NPI-0052]

AG-CN2-0444-C100 100µg

Formula \( \text{C}_{15}\text{H}_{20}\text{ClNO}_{4} \)
MW 313.8
CAS 437742-34-2

Handling / Storage
Shipping BLUE ICE
Short Term Storage +4°C
Long Term Storage -20°C

Keep under inert gas. Protect from light. Protect from moisture and oxygen.

Use / Stability
Stable for at least 1 year after receipt when stored at -20°C.

MSDS available at www.adipogen.com or upon request.

Product Specifications
Source/Host Isolated from *Salinospora tropica*.
Purity ≥95% (HPLC)
Appearance White solid.
Solubility Soluble in DMSO. Do not dissolve in methanol or ethanol.

Other Product Data

Note: We recommend to use fresh solutions. Aliquots should be prepared in DMSO and stored at -20°C.

Product Description

- Potent, irreversible inhibitor of all the 3 proteolytic activities of the mammalian 20S proteasome.
- β5 subunit: chymotrypsin-like (EC\(_{50}\) = 3.5nM)
- β2 subunit: trypsin-like (EC\(_{50}\) = 28nM)
- β1 subunit: caspase-like or peptidyl-glutamyl peptide-hydrolyzing (PGPH) (EC\(_{50}\) = 430nM)

WARNING: Intended for research use only. This product is not intended or approved for human, diagnostics, therapeutic or veterinary use. Use of this product for human or animal testing is extremely hazardous and may result in disease, severe injury, or death. MATERIAL SAFETY DATA: Review the complete Material Safety Data Sheet before use.

For Local Distributors please visit www.adipogen.com
• Potent anticancer compound.
• Triggers apoptosis, with distinct proteasome activity and mechanism of action compared to bortezomib (Velcade) (Prod. No. AG-CR1-3602).
• Most potent suppressor of NF-κB activation, compared with bortezomib, MG-132 (Prod. No. AG-CP3-0011), N-acetyl-leucyl-leucyl-norleucinal (ALLN) and lactacystin (Prod. No. AG-CN2-0104).
• Inhibitor of TNF-α, IL-1, IL-6, ICAM-1 and VEGF synthesis.
• Displays a longer inhibition duration than bortezomib.
• Potent antileukemic activity against bortezomib-resistant leukemia cells.

Product Specific References

4. Crystal structures of Salinosporamide A (NPI-0052) and B (NPI-0047) in complex with the 20S proteasome reveal important consequences of beta-lactone ring opening and a mechanism for irreversible binding: M. Groll, et al.; JACS 128, 5136 (2006)
11. Generating a generation of proteasome inhibitors: from microbial fermentation to total synthesis of salinosporamide a (marizomib) and other salinosporamides: B.C. Potts & K.S. Lam; Mar. Drugs 8, 835 (2010) (Review)


WARNING: Intended for research use only. This product is not intended or approved for human, diagnostics, therapeutic or veterinary use. Use of this product for human or animal testing is extremely hazardous and may result in disease, severe injury, or death. MATERIAL SAFETY DATA: Review the complete Material Safety Data Sheet before use.